EB
The startup develops gene editing therapeutics that target and disrupt viral genes associated with neurotrophic viruses, transforming them into safe and effective treatments. This enables healthcare providers to effectively manage diseases caused by viral infections, improving patient outcomes.
Updated 3 months ago
Funding
$82M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops gene editing therapeutics that target and disrupt viral genes associated with neurotrophic viruses, transforming them into safe and effective treatments. This enables healthcare providers to effectively manage diseases caused by viral infections, improving patient outcomes.